What percentage of benzoyl peroxide actually works?

The U.S. FDA classified benzoyl peroxide as GRASE (generally recognized as safe and effective) for OTC topical acne treatment at 2.5–10% under 21 CFR §333.310 (final rule March 4, 2010). This range reflects the concentrations studied in the OTC drug review process, not a gradient of increasing efficacy. The monograph does not state that 10% is more effective than 2.5% — it sets the outer boundary of what has been reviewed for safety. Products above 10% (once sold by some brands) fall outside this GRASE determination. Below 2.5%, in vitro data show the bactericidal effect requires longer contact time to achieve the same kill rate as higher concentrations, which is why 2.5% is the practical floor for most leave-on applications.

• Review FDA classified benzoyl peroxide as GRASE for OTC topical acne treatment at 2.5–10% (21 CFR §333.310); final rule published March 4, 2010 (75 FR 9767). ⁹
• Study The minimum contact time for a bactericidal effect on C. acnes is nearly immediate with 5% or greater BPO, whereas ≤2.5% BPO requires longer contact time. All concentrations from 1.25% to 10% achieved bactericidal effects against both antibiotic-resistant and antibiotic-susceptible C. acnes strains. ³

The most important concentration finding in BPO literature comes from a 1986 double-blind RCT by Mills, Kligman, Pochi, and Comite (n=65). All three concentrations — 2.5%, 5%, and 10% — outperformed vehicle. Crucially, 2.5% was statistically equivalent to 5% and 10% for reducing inflammatory papule and pustule counts. The 2.5% formulation also significantly reduced P. acnes and free fatty acids within two weeks. Where the concentrations diverged was on the tolerability side: desquamation (skin flaking) and erythema (redness) were significantly more frequent with 10% than with 2.5%. The 5% concentration sat in between. This is the foundational evidence for the standard clinical recommendation: start at 2.5%, which gives you the full efficacy of the class with the least irritation. The Cochrane systematic review of 120 trials (29,592 participants) confirms BPO at 2.5–10% reduces both inflammatory and total lesion counts versus placebo. The review does not establish that higher concentrations produce superior lesion reduction — the evidence for additional benefit above 2.5% is not there.

• Study In a double-blind RCT (n=65), 2.5% benzoyl peroxide gel was equivalent to 5% and 10% concentrations in reducing inflammatory lesion counts. Desquamation and erythema were significantly less frequent with 2.5% than with 10%. ¹
• Study Benzoyl peroxide at concentrations from 2.5% to 20% was assessed across 120 trials (29,592 participants). BPO was effective for reducing both inflammatory and total lesion counts versus placebo. ²

One honest caveat The 2.5%-equivalence finding rests primarily on one RCT (Mills & Kligman 1986, n=65). The study is widely cited, consistent with mechanistic understanding, and supported by the Cochrane pool — but independent large-scale replication with modern formulations has not been published. The practical consensus holds: start at 2.5%.

In the Mills & Kligman trial, 5% and 10% BPO did not reduce inflammatory lesions more than 2.5%. What they did produce was a dose-dependent increase in irritation: dryness, redness, and flaking were significantly more common at 10%. For inflammatory acne — papules and pustules — there is no clinical evidence that you need more than 2.5% to get the maximum achievable response. The one scenario where higher concentrations may have a rationale is wash-off use. In a wash product used for 30–60 seconds, the contact time is short. In vitro data show that 5% or higher achieves a bactericidal effect nearly immediately on contact with C. acnes, while 2.5% and lower concentrations require longer contact time for the same kill. If you are using a wash-off cleanser rather than a leave-on treatment, a 4–5% wash formulation has a theoretical rationale — though direct clinical evidence comparing leave-on 2.5% against wash-off 5% is not established in the sources reviewed here.

• Study In a double-blind RCT (n=65), 2.5% benzoyl peroxide gel was equivalent to 5% and 10% concentrations in reducing inflammatory lesion counts. Desquamation and erythema were significantly less frequent with 2.5% than with 10%. ¹
• Study The minimum contact time for a bactericidal effect on C. acnes is nearly immediate with 5% or greater BPO, whereas ≤2.5% BPO requires longer contact time. ³

Benzoyl peroxide has one clinical advantage that no concentration discussion should leave out: C. acnes has never developed resistance to it. The mechanism is non-specific — BPO decomposes in the follicle into reactive oxygen species that oxidize bacterial proteins and disrupt the C. acnes cell wall simultaneously at multiple sites. There is no single target for resistance mutation to develop against. This contrasts sharply with topical antibiotics like clindamycin and erythromycin, where resistance rates are now substantial globally. In controlled lab testing, C. acnes strains repeatedly exposed to clindamycin alone developed resistance (≥3-fold MIC increase), while identical strains exposed to clindamycin/BPO combinations showed no MIC change over repeated passages. This is why benzoyl peroxide is the recommended companion to topical antibiotic therapy — and why it is the preferred solo active for long-term maintenance. This advantage does not change with concentration. A 2.5% formulation carries the same resistance-proof mechanism as a 10% formulation.

• Study Resistance to C. acnes has not been reported with benzoyl peroxide; in contrast to antibiotics, benzoyl peroxide works rapidly on P. acnes without causing antibiotic resistance. ⁴
• Study Bacterial cultures repeatedly exposed to clindamycin alone developed resistance (≥3-fold MIC increase), while identical strains exposed to clindamycin/BPO combinations showed no change in MIC over repeated passages. ⁵
• Study Benzoyl peroxide generates reactive oxygen species upon skin absorption; these oxidise bacterial proteins and disrupt C. acnes cell walls. A significant reduction in C. acnes occurs within 20 hours of a single application of 5% BPO. ²

In March 2024, the independent laboratory Valisure filed an FDA citizen petition reporting that OTC benzoyl peroxide products can degrade into benzene — a known human carcinogen — at elevated temperatures. Testing at 50°C (simulating accelerated shelf-life conditions) and 70°C (simulating a hot vehicle) produced benzene at levels Valisure reported as over 800× the FDA's conditional 2 ppm limit. FDA conducted its own independent testing of 95 OTC benzoyl peroxide products and announced results on March 11, 2025. The finding was substantially different from Valisure's: more than 90% of products showed undetectable or extremely low benzene levels. Six specific product lots with elevated benzene were voluntarily recalled. FDA stated that cancer risk from these products under normal use is very low. A 2025 peer-reviewed article in Frontiers in Pediatrics confirmed the temperature- and UV-dependence of benzene formation from BPO: cold storage (2°C) produced undetectable benzene, while heat and UV exposure produced more. The practical takeaway: store products at room temperature, away from direct sunlight, and never in a hot vehicle. This is a real storage and handling issue — not a reason to avoid benzoyl peroxide. The controversy does not change the concentration decision: the benzene risk is inherent to the molecule, not proportional to the labeled percentage.

• Study Benzoyl peroxide can thermally decompose into benzene. Testing at 37°C, 50°C, and 70°C showed temperature-dependent benzene formation; cold storage (2°C) produced undetectable benzene, while higher temperatures produced substantially elevated levels. UV exposure also induced significant benzene formation. ⁶
• Review Valisure's March 2024 citizen petition to FDA reported that testing of OTC benzoyl peroxide products at elevated temperatures yielded benzene levels over 800 times the FDA's conditional 2 ppm limit. ⁷
• Review FDA's own testing of 95 benzoyl peroxide acne products (announced March 11, 2025) found that more than 90% had undetectable or extremely low benzene levels. Six product lots with elevated benzene were voluntarily recalled. FDA stated that cancer risk from these products under normal use is very low. ⁸

One honest caveat The FDA and Valisure used different testing methodologies and produced substantially discordant benzene measurements. The real-world benzene exposure from OTC benzoyl peroxide under typical home storage conditions has not been fully resolved by a head-to-head comparison using standardized methodology. The honest position is: store correctly (room temperature, not in a hot car, away from direct sunlight) and follow FDA guidance.

Benzoyl peroxide is a strong oxidizing agent. The same chemistry that destroys C. acnes cell walls will bleach fabric dyes and hair melanin on direct contact. This is not a toxicological concern — it is a practical one. Colored towels, pillowcases, and washcloths in contact with residue from BPO-treated skin will bleach irreversibly. This happens at every concentration in the OTC range. The standard recommendation is white towels and white or old pillowcases while using any strength of benzoyl peroxide. Higher concentrations may bleach fabric faster, but no concentration is safe for colored fabric.

Is higher benzoyl peroxide percentage more effective?

No. The landmark evidence comes from a 1986 double-blind RCT (Mills, Kligman et al., n=65) that compared 2.5%, 5%, and 10% BPO head-to-head. All three reduced inflammatory lesions significantly versus vehicle. The 2.5% and 5% concentrations were statistically equivalent to 10% for lesion reduction — but 10% produced significantly more desquamation and erythema. The Cochrane systematic review of 120 trials (29,592 participants) confirms efficacy across the range but does not show that higher concentrations produce greater lesion reduction. The evidence-based approach: start at 2.5% and only move up if your skin tolerates it and you are not responding. ¹²

What's the difference between a 2.5% wash and a 2.5% leave-on?

Contact time. In vitro data show that 5% or higher BPO achieves a bactericidal effect on C. acnes nearly immediately, while 2.5% and lower concentrations require longer contact time to reach the same kill level. A leave-on treatment at 2.5% has hours of contact with the follicle, which is enough. A wash-off cleanser used for 30–60 seconds and rinsed away has substantially less contact time — which is why wash products often use 4–5% to compensate for the shorter exposure. This is a theoretical rationale supported by in vitro contact-time data; direct clinical comparisons of leave-on 2.5% versus wash-off 5% have not been identified in the sources reviewed here. ³

Does benzoyl peroxide cause antibiotic resistance?

No — and this is one of its most clinically important properties. Benzoyl peroxide kills C. acnes via non-specific oxidative damage: it releases reactive oxygen species that destroy bacterial proteins and cell walls at multiple sites simultaneously, leaving no single target for resistance mutation. In controlled laboratory testing, C. acnes strains exposed to clindamycin alone developed ≥3-fold MIC increases (resistance), while identical strains exposed to clindamycin/BPO combinations showed no MIC change. No C. acnes resistance to benzoyl peroxide has been documented to date in the scientific literature. ⁴⁵

Is benzoyl peroxide safe — should I be worried about benzene?

Standard benzoyl peroxide products stored correctly are considered safe for typical use. The benzene issue is real but context-dependent. In 2024, Valisure reported that BPO can degrade into benzene (a carcinogen) at elevated temperatures, with levels over 800× FDA's 2 ppm conditional limit under extreme heat conditions. FDA conducted independent testing of 95 products in 2025 and found the opposite pattern: more than 90% showed undetectable or very low benzene. Six product lots were voluntarily recalled. A 2025 peer-reviewed review in Frontiers in Pediatrics confirmed that benzene formation is temperature- and UV-dependent — cold storage eliminates it, hot environments produce it. FDA's stated position: cancer risk from these products under normal use is very low. Storage guidance: room temperature, away from direct sunlight, never in a hot car. ⁶⁷⁸

Can I use benzoyl peroxide while pregnant?

Current guidance from the American College of Obstetricians and Gynecologists (ACOG) suggests OTC topical benzoyl peroxide is acceptable for use during pregnancy when needed. The basis is minimal systemic absorption — roughly 5% of the applied dose is metabolized to benzoic acid and renally excreted. The MotherToBaby/OTIS fact sheet (NCBI Bookshelf NBK582985) reflects this position: topical BPO is not expected to increase birth defect risks or pregnancy complications when used as directed. This is not based on prospective controlled studies in pregnant humans — it is based on the minimal-absorption rationale and ACOG guidance. Discuss with your obstetrician if you have concerns. ¹⁰

Will benzoyl peroxide bleach my towels and pillowcases?

Yes, at any concentration. Benzoyl peroxide is a strong oxidizing agent — the same chemistry that kills bacteria will bleach fabric dyes and hair pigment on contact. The bleaching is permanent and happens at every OTC concentration (2.5–10%). Use white or designated old towels and pillowcases while using any benzoyl peroxide product. Residue transfers from skin to fabric even after the product appears to have dried.

1. 1

   Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris

   Mills OH Jr, Kligman AM, Pochi P, Comite H · International Journal of Dermatology 25(10):664-667 · 1986

2. 2

   Topical benzoyl peroxide for acne

   Yang Z, Zhang Y, Lazic Mosler E, Hu J, Li H, Zhang Y, Liu J, Zhang Q · Cochrane Database of Systematic Reviews 2020(3):CD011154 · 2020

3. 3

   Minimum Contact Time of 1.25%, 2.5%, 5%, and 10% Benzoyl Peroxide for a Bactericidal Effect Against Cutibacterium acnes

   Boonchaya P, Rojhirunsakool S, Kamanamool N, Khunkhet S, Yooyongsatit S, Udompataikul M, Taweechotipatr M · Clinical, Cosmetic and Investigational Dermatology 15:403-409 · 2022

4. 4

   The role of benzoyl peroxide in the new treatment paradigm for acne

   Kircik LH · Journal of Drugs in Dermatology 12(6):s73-76 · 2013

5. 5

   Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations in Combating Rising Resistance in Cutibacterium acnes

   Ghannoum M, Gamal A, Kadry A, Del Rosso JQ, Stein Gold L, Kircik LH, Harper JC · Clinical, Cosmetic and Investigational Dermatology · 2025

6. 6

   Benzoyl peroxide in the treatment of acne: are there potential health concerns?

   Czyz S, Yang K, Jafarian F · Frontiers in Pediatrics 13:1599491 · 2025

7. 7

   FDA Citizen Petition #8: Benzene in Benzoyl Peroxide Drug Products

   Valisure LLC · FDA Citizen Petition Docket Filed March 6, 2024 · 2024

8. 8

   Limited Number of Voluntary Recalls Initiated After FDA Testing of Acne Products; Benzene Findings Show More Than 90% of Products at Very Low or Undetectable Levels

   U.S. Food and Drug Administration · FDA Drug Alerts and Statements Announced March 11, 2025 · 2025

9. 9

   Classification of Benzoyl Peroxide as Safe and Effective and Revision of Labeling to Drug Facts Format; Topical Acne Drug Products for Over-The-Counter Human Use; Final Rule

   U.S. Food and Drug Administration · Federal Register 75 FR 9767 (March 4, 2010); codified at 21 CFR Part 333 Subpart D §333.310 · 2010

10. 10

    Topical Acne Treatments — MotherToBaby Fact Sheet

    Organization of Teratology Information Specialists (OTIS) · NCBI Bookshelf · 2023